Pembrolizumab
Nonpapillary Renal Cell Carcinoma
Explore 112 assets in Nonpapillary Renal Cell Carcinoma →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07037004CT.gov Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery | — | Recruiting | — | — | — |
NCT07460206CT.gov Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment | — | Not Yet Recruiting | — | — | — |
NCT07383441CT.gov Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | — | Recruiting | — | — | — |
NCT07187778CT.gov Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE) | — | Recruiting | — | — | — |
NCT06361810CT.gov PSMA Therapy and Immunotherapy in Kidney Cancer | — | Withdrawn | — | — | — |
NCT06661720CT.gov Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | — | Recruiting | — | — | — |
NCT06860386CT.gov Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC | — | Suspended | — | — | — |
NCT06716853CT.gov A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma | — | Terminated | — | — | — |
NCT05585034CT.gov Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors | — | Completed | — | — | — |
NCT05567588CT.gov Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer | — | Unknown | — | — | — |
Show 10 more trialsShow fewer
NCT05581004CT.gov A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05620134CT.gov Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | — | Active Not Recruiting | — | — | — |
NCT05363631CT.gov Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab | — | Active Not Recruiting | — | — | — |
NCT05086692CT.gov A Beta-only IL-2 ImmunoTherapY Study | — | Recruiting | — | — | — |
NCT04995016CT.gov Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma | — | Unknown | — | — | — |
NCT04977453CT.gov GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04370509CT.gov Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery | — | Terminated | — | — | — |
NCT04374877CT.gov Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03260504CT.gov Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer | — | Terminated | — | — | — |
NCT03280667CT.gov Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Nonpapillary Renal Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | City of Hope Medical Center | P3 | B · 62 |
| Girentuximab | Massachusetts General Hospital | P3 | BB |
| Pazopanib | Academic and Community Cancer Research United | P4 | BB |
| Clostridium Butyricum Miyairi 588 | City of Hope Medical Center | P3 | BB |
| Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer | Regeneron Pharmaceuticals | P2 | BB |
| Cabozantinib | SWOG Cancer Research Network | P3 | BB |
| Nivolumab | Fred Hutchinson Cancer Center | P3 | BB |
| Cyclophosphamide | City of Hope Medical Center | P3 | B |
| Irinotecan | M.D. Anderson Cancer Center | P3 | B |
+42 more in the Nonpapillary Renal Cell Carcinoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- GirentuximabMassachusetts General HospitalBB
- PazopanibAcademic and Community Cancer Research UnitedBB
- Clostridium Butyricum Miyairi 588City of Hope Medical CenterBB
- Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, DimerRegeneron PharmaceuticalsBB
- CabozantinibSWOG Cancer Research NetworkBB
Citation
Floatz Terminal. Pembrolizumab in Nonpapillary Renal Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-nonpapillary-renal-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →